

January 3, 2019

COM-2019-002

Recall: Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Consumer Level Recall of 80 Lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP

Dear provider of pharmaceutical services,

At PharmPix we are committed to the health and well-being of patients. It is for this reason that we inform you that on December 31, 2018 the US Food and Drug Administration (FDA) issued a statement notifying that Aurobindo Pharma USA, Inc. is voluntarily recalling of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP. The recall was made because these lots does not meet safety standards due to the presence of the impurity N-nitrosodiethylamine (NDEA), a substance that could cause cancer. The products affected by the recall are detailed on Table 1.

Table 1. Affected products

Product	Affected Lot	Expiration date	NDC
Amlodipine and Valsartan Tablets USP5mg/160mg	VESA17013-A	10/2019	65862-737-30
Amlodipine and Valsartan Tablets USP5mg/160mg	VESA17014-A	10/2019	65862-737-30
Amlodipine and Valsartan Tablets USP5mg/160mg	VESA18001-A	12/2019	65862-737-30
Amlodipine and Valsartan Tablets USP5mg/160mg	VESA18002-A	12/2019	65862-737-30
Amlodipine and Valsartan Tablets USP10mg/160mg	VFSA17008-A	10/2019	65862-739-30
Amlodipine and Valsartan Tablets USP10mg/160mg	VFSA17010-A	10/2019	65862-739-30
Amlodipine and Valsartan Tablets USP10mg/160mg	VFSA18002-A	01/2020	65862-739-30
Amlodipine and Valsartan Tablets USP10mg/160mg	VFSA18003-A	01/2020	65862-739-30
Amlodipine and Valsartan Tablets USP10mg/160mg	VFSA18007-A	03/2020	65862-739-30
Amlodipine and Valsartan Tablets USP10mg/160mg	VFSA18008-A	03/2020	65862-739-30

Table 1. Affected products

Product	Affected Lot	Expiration date	NDC
Amlodipine and Valsartan Tablets USP10mg /320mg	VKSA17008-A	05/2019	65862-740-30
Amlodipine and Valsartan Tablets USP10mg /320mg	VKSA17014-A	10/2019	65862-740-30
Amlodipine and Valsartan Tablets USP10mg /320mg	VKSA17015-A	10/2019	65862-740-30
Amlodipine and Valsartan Tablets USP10mg /320mg	VKSA17016-A	10/2019	65862-740-30
Amlodipine and Valsartan Tablets USP10mg /320mg	VKSA17017-A	10/2019	65862-740-30
Amlodipine and Valsartan Tablets USP10mg /320mg	VKSA18002-A	01/2020	65862-740-30
Amlodipine and Valsartan Tablets USP10mg /320mg	VKSA18004-A	01/2020	65862-740-30
Amlodipine and Valsartan Tablets USP5mg /320mg	VMSA17012-A	11/2019	65862-738-30
Amlodipine and Valsartan Tablets USP5mg /320mg	VMSA17013-A	11/2019	65862-738-30
Amlodipine and Valsartan Tablets USP5mg /320mg	VMSA17014-A	11/2019	65862-738-30
Amlodipine and Valsartan Tablets USP5mg /320mg	VMSA17015-A	11/2019	65862-738-30
Amlodipine and Valsartan Tablets USP5mg /320mg	VMSA17016-A	11/2019	65862-738-30
Amlodipine and Valsartan Tablets USP5mg /320mg	VMSA17017-A	11/2019	65862-738-30
Amlodipine and Valsartan Tablets USP10mg/160mg	VFSA17009-A	10/2019	65862-739-30
Amlodipine and Valsartan Tablets USP 10mg /320mg	VKSA18005-A	03/2020	65862-740-30
Amlodipine and Valsartan Tablets USP 10mg /320mg	VKSA18001-A	01/2020	65862-740-30
Valsartan and Hydrochlorothiazide tablets & USP 320mg/12.5mg	HRSA17033-A	10/2020	65862-550-90
Valsartan and Hydrochlorothiazide tablets & USP 320mg/12.5mg	HRSA17034-A	10/2020	65862-550-90
Valsartan and Hydrochlorothiazide tablets & USP 320mg/12.5mg	HRSA17035-A	10/2020	65862-550-90
Valsartan and Hydrochlorothiazide tablets & USP 320mg/12.5mg	HRSA17036-A	10/2020	65862-550-90
Valsartan and Hydrochlorothiazide tablets & USP 320mg/12.5mg	HRSA17037-A	10/2020	65862-550-90

Table 1. Affected products

Product	Affected Lot	Expiration date	NDC
Valsartan and Hydrochlorothiazide Tablets USP160mg/12.5mg	HTSA17033-A	10/2020	65862-548-90
Valsartan and Hydrochlorothiazide Tablets USP160mg/12.5mg	HTSA17034-A	10/2020	65862-548-90
Valsartan and Hydrochlorothiazide Tablets USP160mg/12.5mg	HTSA17035-A	10/2020	65862-548-90
Valsartan and Hydrochlorothiazide Tablets USP160mg/12.5mg	HTSA17036-A	10/2020	65862-548-90
Valsartan and Hydrochlorothiazide Tablets USP160mg/12.5mg	HTSA17040-A	10/2020	65862-548-90
Valsartan and Hydrochlorothiazide Tablets USP160mg/12.5mg	HTSA17041-A	11/2020	65862-548-90
Valsartan and Hydrochlorothiazide Tablets USP160mg/12.5mg	HTSA17042-A	11/2020	65862-548-90
Valsartan and Hydrochlorothiazide Tablets USP160mg/12.5mg	HTSA17043-A	11/2020	65862-548-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB17049-A	08/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB17054-A	10/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB17055-A	10/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB17056-A	10/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB17057-A	10/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB17058-A	10/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB17059-A	10/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB17060-A	10/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB17062-A	10/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB17066-A	10/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB17067-A	11/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB17068-A	11/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB17069-A	11/2020	65862-551-90

Table 1. Affected products

Product	Affected Lot	Expiration date	NDC
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB18001-A	12/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB18002-A	12/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB18003-A	12/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB18003-A	12/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB18004-A	12/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB18005-A	12/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB18006-A	12/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB18007-A	12/2020	65862-551-90
Valsartan and Hydrochlorothiazide tablets USP 80mg/12.5mg	HVSA17011-A	11/2020	65862-547-90
Valsartan and Hydrochlorothiazide tablets USP 80mg/12.5mg	HVSA17012-A	11/2020	65862-547-90
Valsartan and Hydrochlorothiazide tablets USP 80mg/12.5mg	HVSA18001-A	12/2020	65862-547-90
Valsartan and Hydrochlorothiazide tablets USP 160mg/25mg	HVSB17023-A	08/2020	65862-549-90
Valsartan and Hydrochlorothiazide tablets USP 160mg/25mg	HVSB17036-A	11/2020	65862-549-90
Valsartan and Hydrochlorothiazide tablets USP 160mg/25mg	HVSB17037-A	11/2020	65862-549-90
Valsartan and Hydrochlorothiazide tablets USP 160mg/25mg	HVSB17038-A	11/2020	65862-549-90
Valsartan and Hydrochlorothiazide tablets USP 160mg/25mg	HVSB17039-A	11/2020	65862-549-90
Valsartan and Hydrochlorothiazide tablets USP 160mg/25mg	HVSB17040-B	11/2020	65862-549-90
Valsartan and Hydrochlorothiazide tablets USP 160mg/25mg	HVSB18001-A	12/2020	65862-549-90
Valsartan and Hydrochlorothiazide tablets USP 160mg/25mg	HVSB18002-A	12/2020	65862-549-90
Valsartan and Hydrochlorothiazide tablets USP 160mg/25mg	HVSB18003-A	12/2020	65862-549-90
Valsartan and Hydrochlorothiazide tablets USP 160mg/25mg	HVSB18004-A	12/2020	65862-549-90

Table 1. Affected products

Product	Affected Lot	Expiration date	NDC
Valsartan and Hydrochlorothiazide Tablets USP 160mg/12.5mg	HTSA17037-A	10/2020	65862-548-90
Valsartan and Hydrochlorothiazide Tablets USP 160mg/12.5mg	HTSA17039-A	10/2020	65862-548-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB17063-A	10/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB17064-A	10/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP 320mg/25mg	HTSB17065-A	10/2020	65862-551-90
Valsartan and Hydrochlorothiazide Tablets USP & 320/25mg	HTSB18029-A	03/2021	65862-551-90
Valsartan Tablets USP 320mg	VUSD17008-A	07/2019	65862-573-90
Valsartan Tablets USP 320mg	VUSD17009-A	09/2019	65862-573-90

The Pharmacy must:

1. Identify if they have the product in inventory and immediately stop using and dispensing the product.
2. Contact all members that in the previous 90 days received the recalled medication and advised them to talk to their doctor. Patients should not discontinue taking the medication without a doctor’s permission.
3. Contact Inmar\CLS-Medturn at 1-877-208-2407 or email rxrecalls@inmar.com. Normal business hours are 9:00 am -5:00 pm Eastern Time.

For additional information visit:

<https://www.fda.gov/Safety/Recalls/ucm629213.htm>

Department of Clinical Pharmacy